Shots:

• The EC’s approval is based on P-III ARAMIS study assessing Nubeqa (600mg- bid) + ADT vs PBO + ADT 1-509 patients in a ratio (2:1) with nmCRPC
• The P-III ARAMIS study results: improvement in 1EPs of MFS (40.4 vs 18.4mos.)- showed a delay in time to pain progression. Time to cytotoxic CT and time to SSE also demonstrated a benefit in favor of Nubeqa at the time of final MFS analysis
• Nubeqa is an ARi that binds to the receptor with high affinity- thus inhibiting the growth of prostate cancer cells and is an approved therapy in the US- Brazil- Australia- Canada- and Japan

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Lucky step